EUCTR2014-004176-35-Outside-EU/EEA
Active, not recruiting
Not Applicable
Evaluation Of The Efficacy Of A Novel Ibuprofen Formulation In The Treatment Of Post Surgical Dental Pain: Study I
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Post Surgical Dental Pain
- Sponsor
- Pfizer
- Enrollment
- 316
- Status
- Active, not recruiting
- Last Updated
- 10 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Males and females 16 years to 40 years of age (inclusive).
- •2\. Outpatients who have moderate to severe post\-operative pain (confirmed by a Visual Analog Scale Pain Severity Rating Scale (VAS\-PSR) score of at least 50 mm on a 100\-mm VAS\-PSR) following surgical extraction of two or more third molars, at least one of which must be a partial or complete bony mandibular impaction.
- •3\. Use of only the following pre\-operative medication(s)/anesthetic(s): topical benzocaine, a short\-acting parenteral (local) anesthetic (mepivacaine or lidocaine) with or without vasoconstrictor and/or nitrous oxide.
- •4\. Examined by the attending dentist or physician and medically cleared to participate in the study.
- •5\. In general good health and have no contraindications to the study or rescue medication.
- •6\. Reliable, cooperative, and of adequate intelligence to record the requested information on the analgesic questionnaire form.
- •7\. Subjects (or the parent or legal guardian of subjects under the age of 18 years) are required to read, comprehend, and sign the informed consent. Subjects requiring a parent or legal guardian to sign the informed consent form will also be required to sign an assent.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 111
- •F.1\.2 Adults (18\-64 years) yes
Exclusion Criteria
- •1\.Presence or history of any significant hepatic, renal, endocrine, cardiovascular, neurological, psychiatric, gastrointestinal, pulmonary, hematologic, or metabolic disorder determined by the Principal Investigator to place the subject at increased risk.
- •2\.Use of a prescription or over\-the\-counter (OTC) drug with which administration of ibuprofen or any other non\-steroidal anti\-inflammatory drug (NSAID), acetaminophen (APAP), or hydrocodone is contraindicated (including: opioids, antipsychotics, antianxiety agents, or other central nervous system depressants \[including alcohol]).
- •3\. Use of prescription or OTC antihistamines within 24 hours prior to taking study medication. (Note exceptions: loratadine \[Claritin], desloratadine \[Clarinex], cetirizine \[Zyrtec ], levocetirizine \[Xyzal], fexofendadine \[Allegra], and azelastine \[Intranasal, Astelin]).
- •4\. Use of a bisphosphonate (e.g., pamidronate \[Aredia], risedronate \[Actonel], alendronate \[Fosamax], or ibandronate \[Boniva]) in the past 5\-years.
- •5\. Acute localized dental alveolar infection at the time of surgery that could confound the post\-surgical evaluation.
- •6\. Female subjects who are pregnant, lactating, of child\-bearing potential or post\-menopausal for less than 2 years and not using a medically approved method of contraception (i.e., oral, transdermal, or implanted contraceptives, intrauterine or intravaginal device \[IUD or NuvaRing ], diaphragm, condom, abstinence, or surgical sterility including partner’s vasectomy), or who test positive on a urine\-based pregnancy test.
- •7\. Presence or history (within 2 years of enrollment) of gastrointestinal ulcer or gastrointestinal bleeding.
- •8\. Presence or history (within 2 years of enrollment) of a bleeding disorder.
- •9\. Presence or history of alcohol (3 or more alcoholic drinks per day on a regular basis) or substance abuse within 2 years of enrollment (note: one drink of alcohol is 1 oz. liquor, 6 oz. wine, or 12 oz. beer) or currently abusing other mood\-altering drugs (e.g., cannabis). Patients who are taking St. John’s Wort, or any other nutritional supplement known to have psychotropic effects may be enrolled if they have been on stable doses of medication for at least 2 months, will maintain this dose throughout the study, and their condition is judged by the Principal Investigator to be well\-controlled.
- •10\. Habituation to analgesic medications (i.e., routine use of oral analgesics 5 or more times per week).
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Ibuprofen and morphine for acute pain in sickle cell diseaseSickle cell diseaseHaematological DisordersSickle-cell disordersISRCTN97241637orth West London Hospitals NHS Trust (UK)320
Active, not recruiting
Phase 1
An Evaluation of the Effectiveness of Ibuprofen and Morphine for Acute Pain in Sickle Cell Disease - Ibuprofen and Morphine for Acute Sickle Cell PaiSickle Cell DiseaseEUCTR2008-006846-24-GBorth West London Hospitals NHS Trust320
Completed
Phase 3
Study Evaluating A Novel Ibuprofen Formulation In The Treatment Of Dental PainPainNCT01216163Pfizer218
Active, not recruiting
Not Applicable
Study comparing ibuprofen and ibuprofen arginine in the control of spontaneous pain in patients with osteoarthritis and stabilized hypertension.EUCTR2011-003826-28-ITZAMBON S.p.A.
Completed
Phase 3
Study Evaluating A Novel Ibuprofen Formulation In The Treatment Of Dental PainPainNCT01098747Pfizer335